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Mitochondria are cytosolic organelles that have many essential roles
including ATP production via oxidative phosphorylation, apoptosis, iron-
sulfur cluster biogenesis, heme and steroid synthesis, calcium homeostasis,
and regulation of cellular redox state. One of the unique features of these
organelles is the presence of an extrachromosomal mitochondrial genome
(mtDNA), together with all the machinery required to replicate and tran-
scribe mtDNA. The accurate maintenance of mitochondrial gene expres-
sion is essential for correct organellar metabolism, and is in part dependent
on the levels of mtDNA and mtRNA, which are regulated by balancing
synthesis against degradation. It is clear that although a number of mito-
chondrial nucleases have been identified, not all those responsible for the
degradation of DNA or RNA have been characterized. Recent investiga-
tions, however, have revealed the contribution that mutations in the genes
coding for these enzymes has made to causing pathogenic mitochondrial
diseases.
Introduction
Mitochondria are cytosolic organelles that have many
essential roles including ATP production via oxidative
phosphorylation, apoptosis, iron-sulfur cluster biogen-
esis, heme and steroid synthesis, calcium homeostasis,
and regulation of cellular redox state. One of the
unique features of these organelles is the presence of
an extrachromosomal mitochondrial genome
(mtDNA), together with all the machinery required to
replicate and transcribe mtDNA. The accurate mainte-
nance of mitochondrial gene expression is essential for
correct organellar metabolism, and is in part depen-
dent on the levels of mtDNA and mtRNA, which are
regulated by balancing synthesis against degradation.
It is clear that although a number of mitochondrial
nucleases have been identified, not all those responsible
for the degradation of DNA or RNA have been char-
acterized. Recent investigations, however, have
revealed the contribution that mutations in the genes
coding for these enzymes has made to causing patho-
genic mitochondrial diseases [1,2].
Characterizing mitochondrial nucleases is particu-
larly demanding as these may be present in more than
one cellular compartment, for example, REXO2 is an
RNase that is present in both mitochondria and cyto-
sol. As a result, the biochemical classification of nucle-
ases as truly mitochondrial rather than as a
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contaminant during purification can be challenging.
Despite these difficulties, several human mitochondrial
nucleases have been characterized, although the exis-
tence or the activity of some of these enzymes is still
debated.
Most of the identified DNases are involved in
mtDNA maintenance or repair, and almost all have
both endo- and exonucleolytic activity, although some
such as EndoG also recognize RNA as a substrate [3].
The mitochondrial RNases that have been identified
are, predictably, involved in mtRNA processing and
degradation; however, a few may play a role in
mtDNA replication but their exact function in this
process is controversial. Interestingly, none of the
ribonucleases characterized so far possess 50–30 exonu-
clease activity. The current catalog of mitochondrial
nucleases is unlikely to be comprehensive as evidenced
by recent publications, which increasingly highlight
how dysfunction of these enzymes can cause patho-
genic mitochondrial disease [1].
Tailoring and targeting of specific nuclease activities
to mitochondria, however, is gaining increasing atten-
tion as a therapeutic tool to remove mutated mito-
chondrial DNA and thereby ameliorate disease [4].
This review summarizes the recent advances in char-
acterizing mitochondrial nucleases (Fig. 1), and the
approach of engineering nucleases to be mitochondri-
ally targeted as a tool to manipulate human mtDNA,
with the long-term goal of treating human mitochon-
drial dysfunction.
Mitochondrial DNases
The number of mtDNA molecules that are found in
human cells can vary from a few hundred to more
than a thousand. This mtDNA is organized into com-
plexes known as nucleoids. These structures not only
include TFAM (mitochondrial transcription factor A)
to package the mtDNA [5], but can also associate with
other proteins and enzymes that are responsible for
essential mtDNA-related processes such as replication,
recombination, and repair [6]. Both the replication and
maintenance of mtDNA require the activity of nucle-
ases, mainly DNases, with different levels of specificity
(Table 1). Most of the mitochondrial DNases charac-
terized so far are involved in mtDNA repair [7] and/or
the removal of primers during replication [8].
Although the activity and localization of most of these
Fig. 1. Sketch to indicate the known nucleases and their substrates in human mitochondria. The intermembrane space (IMS) is indicated in
yellow and the matrix in blue. DNases are designated in dark blue and the RNases in red.
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enzymes has been established, whether or not they are
actually involved in mtDNA repair is still debated.
One of the first DNases to be studied was AP
endonuclease 1 (APE1), which is localized to both
mitochondria and the nucleus [9]. It has been shown
to be an essential component of the mitochondrial
base excision repair (BER) pathway [10,11], which is
the main repair mechanism documented in mitochon-
dria. As an endonuclease, APE1 generates a nick at
apurinic/apyrimidinic sites that are produced by DNA
glycosylases during the removal of damaged bases.
This cleavage leaves a 30 terminus with a hydroxyl resi-
due, which is used for DNA synthesis, and a 50 termi-
nal phosphate residue, which is subsequently
dephosphorylated and ligated with newly synthesized
DNA. APE1 has also been shown to have a minimal
30 phosphatase activity [12] prompting another poten-
tial role during BER.
Another AP endonuclease shown to localize to both
the mitochondria and nucleus is APE2 [13]. This
endonuclease is thought to be involved in the BER
pathway, but thus far its mitochondrial activity has
not been demonstrated. APE2 also acts as a 30–50
exonuclease preferentially targeting mismatched 30
nucleotides [14]. This activity could potentially act dur-
ing the mismatch repair to remove mitochondrial
DNA fragments containing mispaired regions. Cur-
rently, this is the only enzyme that demonstrates
in vitro 30–50 DNA exonuclease activity and is localized
to mitochondria.
Long-patch base excision repair (LP-BER) occurs in
human mitochondria and specifically requires a 50-exo/
endonuclease activity [15]. During LP-BER, the strand
break formation produces a 50 single-stranded DNA
flap, which has to be processed to generate the correct
DNA fragment in place for the final ligation step. In
humans, the nuclease-helicase DNA2 belongs to the
PD-(D/E)XK superfamily. It shares homology with
the bacterial RecB nuclease and is localized to both
the mitochondria and nucleus [16,17]. Cleavage activity
assays performed in vitro have demonstrated a speci-
ficity for DNA intermediates that contain 50-flaps [18].
In yeast, DNA2 interacts genetically and biochemically
with FEN1 (Flap endonuclease 1), a member of the
XPG/RAD2 family of endonucleases [19], and subse-
quent work has also confirmed their interaction in
nuclei and shown that the two proteins are associated
with Okazaki fragment maturation [20,21]. Interest-
ingly, when tested in vitro DNA2 and FEN1 are able
to increase the efficiency of flap fragment maturation
[16]. The interactions between these two proteins have
been demonstrated experimentally in yeast, and
although the involvement of FEN1 in mitochondrial
BER [22] and the maintenance of mtDNA integrity
has been demonstrated [23], the localization of FEN1
in human mitochondria is still debated. Recently, Holt
and colleagues have also reported a shorter mitochon-
drial FEN1 isoform, named FENMIT, which could
potentially stabilize R-loop regions through its ability
to bind, but not to cleave, RNA flap fragments [24].
It is believed that more DNases are required to
complete LP-BER. One of these, EXOG (endonuclease
G-like-1), is implicated in the repair of single-strand
breaks in the mitochondrial genome [25]. However, the
depletion of EXOG in rat cardiomyocytes does not
cause any loss of mtDNA integrity, although it does
affect normal mitochondrial function by increasing
ROS production [26]. EXOG is a dimeric endo/50–30
exonuclease that localizes to mitochondria, specifically
to the intermembrane space (IMS). The enzyme has
also been found delineating the cristae, which suggests
it is associated with inner mitochondrial membrane
(IMM) [27]. This is consistent with the distribution of
mtDNA, which is packed into nucleoids that are also
Table 1. Mitochondrial DNases.
Nuclease
Accession
(UNIPROT) Mitochondrial process(es) Cleavage activity(ies)
Substrate
ReferencesDNA RNA
APE1 P27695 Base excision repair Endonuclease U [9–12]
APE2 Q9UBZ4 Base excision repair Endonuclease U [13,14]
dsDNA 30–50 exonuclease
DNA2 P51530 Flap intermediates processing Endonuclease U [16–18,20,21]
FEN1 P39748 Flap intermediates processing
base excision repair
50-flap endonuclease;
50–30 exonuclease;
RNase H activity
U U [16,19–24]
EXO G Q9Y2C4 Single strand break repair Endo/50–30 exonuclease U U [25–27]
ENDO G Q14249 Apoptosis Endonuclease U U [28–32]
MGME1 Q9BQP7 Flap intermediates processing
base excision repair
ssDNA 50–30 exonuclease
ssDNA 30–50 exonuclease
U [33–35]
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associated with the matrix face of the inner mitochon-
drial membrane.
Enzymes involved in the metabolism of mitochon-
drial nucleic acids are expected to localize to the
matrix. Surprisingly, however, several mitochondrial
nucleases have been found in the IMS and the mecha-
nism by which these nucleases act on the mtDNA or
mtRNA located in the matrix remains obscure.
Endonuclease G (Endo G) is a paralogue of EXOG,
which also localizes to the mitochondrial IMS [28]. It
belongs to the superfamily of bba-Me-finger nucleases
and is able to target both DNA and RNA substrates.
Initially, it was postulated that EndoG was responsible
for generating primers for mtDNA replication as it
possesses RNase H activity [29]. It has since been
shown that this nuclease participates in a caspase-
independent apoptotic pathway, as the localization
changes from mitochondrial to nuclear, in which com-
partment it promotes chromatin DNA fragmentation
independently of caspases [30]. Although the involve-
ment of mitochondrial EndoG in apoptosis has been
studied in different model organisms and universally
accepted [30–32], its mitochondrial function still needs
to be elucidated.
One of the more recently characterized human mito-
chondrial nucleases is MGME1, also known as Ddk1
[33,34]. Like DNA2, it belongs to the PD-(D/E)XK
superfamily and shows a preferential 30–50 activity on
single-stranded DNA molecules. Falkenberg and col-
leagues have reconstituted mtDNA replication in vitro
and using this system have demonstrated that
MGME1 is able to process 50-flap intermediates, cru-
cial for the RNA primer removal during mtDNA
replication, into ligatable nicks in combination with
DNA polymerase [35]. MGME1 is clearly a
constituent of the mitochondrial replisome [36], how-
ever, due to its ability to cleave 50-flap substrates, it is
reasonable to hypothesize an additional involvement in
LP-BER during mtDNA repair process together with
DNA2 and FEN1 [35].
Mitochondrial RNases
The human mitochondrial genome is transcribed as
polycistronic units. This process gives rise to one short
and two long transcripts. The former encompasses a
ribosomal RNA transcription unit while the remaining
two essentially transcribe the whole mtDNA molecule
[37]. Each of these transcription units needs to be pro-
cessed in order to release the mt-rRNAs, mt-tRNAs,
and the open reading frames, all of which require speci-
fic modifications to produce the mature form of the
RNA species. The initial processing requires a specific
series of mitochondrial ribonucleolytic activities [38]
(Table 2). In recent years, different research groups
have shown that when labeled by 5-bromouridine
(BrU) these RNA processing enzymes can be found
together with mtRNA and other factors in well-orga-
nized punctate structures, named RNA granules [39–
42]. It is probable that mitochondrial RNA granules
can associate, even if transiently, with transcriptionally
active nucleoids to ensure an efficient coordination of
synthesis, maturation, and translation of mitochondrial
RNA [43,44].
One of the mitochondrial RNases that has been
found in RNA granules is polynucleotide phosphory-
lase (PNPase) [45]. The first evidence of its localization
in human mitochondria was obtained more than
10 years ago when this enzyme was shown to have a
cleavable mitochondrial presequence and that it
Table 2. Mitochondrial RNases.
Nuclease
Accession
(UNIPROT) Mitochondrial process(es) Cleavage activity
Substrate
ReferencesDNA RNA
PNPase Q8TCS8 RNA import; mtRNA degradation 30–50 exonuclease U [45–52]
REXO2 Q9Y3B8 OligoRNA degradation 30–50 exonuclease U U [53]
RNase MRP Primer generation for mtDNA replication Endonuclease U [55–58]
RNase H1 O60930 Primer processing
mtDNA repair
Endonuclease U [59,60,62–65] [66]
RNase P (MRPP1) Q7L0Y3 tRNA 50 end processing (MRPP3)
tRNA methylation (MRPP1 and MRPP2)
Endonuclease U [77,78]
[76]
[72–75]
RNase P (MRPP2) Q99714
RNase P (MRPP3) O15091
ELAC2 (RNase Z 2) Q9BQ52 tRNA 30 end processing Endonuclease U [43,61,70,71,79,81]
PDE12 Q6L8Q7 RNA deadenylation
tRNATyr 30 end processing
30–50 exonuclease U [38,78,82]
[83]
LACTB2 Q53H82 mtRNA degradation? Endonuclease U [84]
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differed from the cytosolic form [46]. PNPase is a
bifunctional enzyme, having both a 30–50 phospho-
rolytic activity and a 50–30 polymerase activity. Since it
exhibited degradation activity, it was initially consid-
ered the ideal candidate to be the main mtRNA
degrading nuclease. Since then conflicting data have
been published from different laboratories generating
debate about the mitochondrial function of this
enzyme. While Nagaike and colleagues observed that
following depletion of PNPase, there was no effect on
the steady-state levels of mt-mRNA, only an altered
polyadenylation status [47]; other groups have shown
that the reduced PNPase affects the level of both
mature mRNAs and their precursors [48,49]. The vari-
ance in the data may result from the different
approaches that were used to deplete PNPase (tran-
sient or stable RNAi interference). To further con-
found the understanding of its function, other studies
have shown that the enzyme is localized within inter-
membrane space and is responsible for the import of
specific cytosolic RNAs into mitochondria [49].
In vitro assays with purified recombinant PNPase show
that it forms a heteromeric complex with the helicase
SUV3 and efficiently degrades structured single-
stranded RNAs [50]. Further in vitro experiments have
shown that PNPase and SUV3 can form a transient
complex with the poly(A) polymerase (mtPAP) in
order to modulate mt-mRNA poly(A) tail lengths in
response to energy changes [51]. Finally, recent work
has shed some light on the in vivo function of PNPase
[45]. This study has demonstrated that the enzyme is
present and active in the mitochondrial matrix and
when interacting with SUV3, constitutes the so-called
mitochondrial degradosome, which colocalizes with
RNA granules.
The end product of such mitochondrial mRNA
degradation is short oligoribonucleotides. PNPase is
not able to degrade RNA fragments < 4 nucleotides in
length [52], and if not completely degraded, these short
oligonucleotides would accumulate and could interfere
with either transcription or replication processes, or
affect the levels of the mitochondrial ribonucleotide
pool. Recently, a ribonuclease, REXO2, has been iden-
tified and characterized in human mitochondria [53].
This enzyme is a member of the DEDD nuclease
superfamily, named for the four conserved acidic resi-
dues that are crucial for the catalytic activity. REXO2
is a conserved exonuclease and possesses the in vitro
ability to degrade small single-stranded RNAs, and
also DNA fragments, in a 30–50 direction [54]. This
oligo-RNase was demonstrated to be active in human
mitochondria and its depletion caused a significant
decrease in both mtDNA and mtRNA levels as well as
a consequential impairment of de novo mitochondrial
protein synthesis [53]. Intriguingly, REXO2 has shown
a dual submitochondrial localization that is reminis-
cent of PNPase, as it is present in both the IMS and
matrix. It is possible that this oligospecific RNase
transiently interacts with mitochondrial degradosome
to complement the otherwise absent degradation, how-
ever, no experimental evidence has been obtained so
far. Another interesting feature is the loss of mito-
chondrial 7S DNA in REXO2-depleted cells. A similar
result has been found in cells overexpressing either
POLcb, the accessory subunit of mtDNA polymerase,
or MGME1 [34]. These data, taken together with the
ability of REXO2 to cleave small DNA fragments,
suggests a possible role in mtDNA replication.
Almost 30 years ago, the Clayton laboratory identi-
fied and partially purified from mouse mitochondria
an endonucleolytic RNase activity [55]. This enzyme,
named RNase mitochondrial RNA processing (RNase
MRP), is a ribonucleoprotein composed of nuclear-
encoded protein and RNA elements [56]. It is located
in multiple cellular compartments namely, the nucleo-
lus, cytosol, and mitochondria. Identification in these
different compartments coupled with the high abun-
dance of the enzyme in the nucleus prompted debate
over the mitochondrial function. Other studies have
shown that in vitro RNase MRP can cleave R-loop
substrates at the physiological priming sites, which
would promote the mtDNA leading-strand replication
[57]. In contrast, an RNase MRP-independent mecha-
nism for primer formation was proposed as potentially
coexisting with the enzymatic cleavage model [58].
The recent hypotheses about the primer processing
and removal, as part of the mtDNA replication pro-
cess, invoke the formation of flap intermediates and
the involvement of different mitochondrial nucleases
(reviewed in [8]). In addition to DNA2, FEN1, and
MGME1, RNase H1 is an endoribonuclease poten-
tially implicated in both mtDNA replication and
repair. It localizes to the mitochondria showing a clas-
sic targeting sequence, but it is synthesized only from
the first of the two in-frame methionine codons in the
transcript [59,60]. Intriguingly, this pattern is shared
by other mitochondrial RNases that have dual or mul-
tiple cellular localizations, including REXO2 [53] and
ELAC2 [61].
RNase H1 possesses a hybrid binding domain
(HBD) that allows it to specifically digest the RNA
strand of RNA/DNA heteroduplexes [62]. In particu-
lar, it cleaves DNA : RNA substrates leaving a two
ribonucleotide overhang at the 50 end of the DNA,
implying the need for a further nuclease activity to
complete primer processing. RNase H1 has been
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shown to play a crucial role in regulation of mtDNA
levels during embryogenesis as knockout mice show
decreased mtDNA content and embryonic lethality
[63]. Replication of mtDNA may require long frag-
ments of DNA : RNA hybrids as intermediates and
RNase H1 activity could be indispensable for their
degradation [64]. Murine embryonic fibroblasts lacking
RNase H1 have been shown to retain primers that are
important for replication initiation both within the D-
loop and at the origin of light strand replication
impeding the progression of polymerase gamma in
subsequent rounds of replication [65]. In addition, the
importance of RNase H1 for mitochondrial genome
maintenance have been recently highlighted by func-
tional analyses performed on patient tissues and cells
carrying pathological mutations in RNASEH1 gene
[66].
One of the features of mammalian mtDNA is the
distribution of the tRNA genes, such that they are
interspersed between the rRNA and mRNA genes. In
most cases, the resulting polycistronic transcripts are
processed according to the ‘tRNA punctuation model’
to release individual RNA species [67] ready for subse-
quent maturation. This model requires the presence of
RNases with endoribonucleolytic activity that act at
the 50- or 30-end of each tRNA. Both these activities
have been identified in human mitochondria and the
proteins responsible, RNase P and ELAC2, respec-
tively, have been characterized (reviewed in [68]).
Where there are no mt-tRNAs between the open read-
ing frames, there must be an mt-tRNA-independent
mechanism in action that has currently evaded charac-
terization (reviewed in [69]), although ELAC2 involve-
ment has been eliminated as a candidate for separating
RNA14 from MTCO3 [70,71].
Mitochondrial RNase P was identified as the
endonuclease responsible for the removal of 50 tRNA
extensions and is composed by three protein subunits,
encoded by different genes that are MRPP1, MRPP2,
and MRPP3. The subunit accountable for the catalytic
activity on mitochondrial tRNA 50-ends is MRPP3
and shows a unique feature, considering the ribozymal
origin of this enzyme: in contrast with nuclear RNase
P, it has no RNA component [72,73]. However, the
catalytic site of MRPP3 is distorted in the absence of
MRPP1 and MRPP2, its nuclease activity seems to be
dependent on the other two subunits and a mouse
model with a tissue specific knockout of MRPP3 has
demonstrated that MRPP3 is essential [74,75].
Although MRPP2 was initially characterized as a
dehydrogenase [76], together with MRPP1 it can form
a subcomplex with methyltransferase activity that can
modify both adenosine and guanine of most mt-
tRNAs at position 9, a modification that appears to
be crucial for the correct mt-tRNA folding [77]. Fur-
ther, this methyltransferase activity is preserved in
fibroblasts from individuals with recessive mutations in
MRPP1 gene (TRMT10C) where mtRNA processing
is affected, resulting in accumulation of mtRNA pre-
cursors [78].
First identified as a candidate prostate cancer sus-
ceptibility gene [79], ELAC2 encodes an endonuclease
that displays RNase Z activity, by acting on the 30 end
of tRNA molecules, but only after RNase P processing
of 50 termini [70,75,80]. In contrast to RNase P,
ELAC2 is active as a single subunit [61] and needs to
be associated with mitochondrial nucleoids to initiate
mtRNA processing [43]. Although depletion of
ELAC2 in HeLa cells caused a decreased level of sev-
eral mitochondrial tRNAs, neither the mt-mRNA/mt-
rRNA levels, mitochondrial protein synthesis nor
OXPHOS were significantly affected [71]. In contrast,
RNA processing defects associated with mitochondrial
translation and respiratory chain dysfunction have
been observed in individuals carrying ELAC2 missense
mutations [81]. Further characterization is required to
elucidate why ELAC2-mediated endonucleolytic cleav-
age would require free 50 ends.
Mitochondrial gene expression is controlled by the
balance of synthesis and degradation of transcripts,
which in turn modulated by other factors such as
polyadenylation. Other than completion of termination
codons on seven open reading frames, the function of
mitochondrial poly(A) tails in mtRNA turnover and/
or translation, has not been determined. The length of
this modification is potentially regulated by the actions
of poly(A) polymerase (mtPAP) with the LRP SLIRP
complex, and the nuclease, PDE12 [38,78]. This 20-
phosphodiesterase localized to the mitochondrial
matrix [82]. It has both in vitro and in vivo 30–50
exonuclease activity, demonstrating preferential cleav-
age of A stretches. In addition to its function on mt-
mRNA, PDE12 has been also shown in vitro to trim
oligo(A) tails to a single A at the 30-termini of mito-
chondrial tRNATyr, thereby completing tRNATyr, as
the mtDNA sequence lacks the terminal 30-adenosine
[83].
In this complex panorama of mitochondrial ribonu-
cleases that act on mtRNA at different stages, neither
an 50–30 exoRNase activity nor an endoRNase active
on mitochondrial transcripts had been detected in the
matrix until the report on LACTB2 (b-lactamase-like-
protein 2) [84]. This enzyme is described as specifically
targeting single-stranded RNA substrates in in vitro
endoribonucleolytic activity assays. In cultured cells,
depletion of this protein causes an accumulation of a
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subset of mitochondrial transcripts and overexpression
of LACTB2 has the opposite effect. However, these
effects are potentially too modest for an enzyme that
should be critical for mtRNA degradation in human
mitochondria. Further investigations are required to
confirm the in vivo role of LACTB2 in mtRNA pro-
cessing, and to answer several remaining questions
concerning missing ribonucleases including: is mt-
mRNA degradation initiated by an endonucleolytic
cleavage? If so, which enzyme(s) is responsible for this
cleavage? Are 50–30 exonucleases actually required for
the complete degradation of mt-mRNA? Since there is
no tRNA gene placed between ATP8 and COX3
genes, is the maturation of ATP6/8 and COX3
mRNAs dependent upon an as yet uncharacterized
nuclease?
Targeting engineered nucleases to
mitochondria: a tool to combat
mtDNA-related disorders
Since each cell contains multiple copies of the mito-
chondrial genome, it is possible that different mtDNA
molecules, carrying mutations or polymorphisms, can
coexist in the same cell. The balance between wild-type
and mutant copies, a state known as heteroplasmy, is
an important factor in determining whether or not
there are pathological consequences that result in
mitochondrial diseases [85,86].
Many approaches have been designed to try and
redress the balance in favor of the wild-type mtDNA
(Fig. 2) [4]. One of the most promising strategies to
ameliorate mitochondrial disorders is to change the
balance of mutated mtDNA molecules in favor of the
wild-type (‘heteroplasmy shift’) by expressing mito-
chondrially targeted endonucleases that could specifi-
cally eliminate mutated mtDNA copies and thereby
decrease their number to below a ‘safe’ threshold [87].
So far, three different nucleolytic activities have given
promising results: restriction endonucleases (REs),
transcription activator-like effector nucleases
(TALENs), and zinc finger nucleases (ZFNs). Mito-
chondrially targeted REs have been used for more
than 15 years. These are designed to have selective
recognition of restriction sites that have been created
as a consequence of the mutation within the mitochon-
drial genome. TALENs and ZFNs are both designer
nucleases consisting of a specific modular DNA-bind-
ing domain (TALE and zinc finger, respectively) and a
sequence-independent nuclease domain. The nuclease
activity is provided by the restriction enzyme FokI,
which needs to dimerize to cleave DNA; however, the
FokI domains are generally modified to prevent off-
target effects due to self-dimerization. This allows the
specific targeting of mtDNA sequences by engineering
TALE and zinc finger domains that are different in
the modularity of DNA recognition [88].
To date, mitochondrial REs have been successfully
expressed in several cellular systems, and in mice, by
use of adenoviral transduction. Constructs that have
been injected in specific mouse tissues in this manner
have shown convincing switches in the levels of hetero-
plasmy [88]. RNA ‘restriction endonucleases’ have also
been engineered and targeted to mitochondria with the
different aim of silencing mitochondrial gene expres-
sion at the transcript level [89]. A limiting factor in the
use of restriction nucleases to decrease the mutant load
of mtDNA is that mutations have to introduce specific
sequences that are recognized by the enzymes as
restriction sites. To circumvent this problem, a range
of mitochondrial nucleases have been successfully
Fig. 2. Sketch to illustrate the consequences of using different
nucleases to target mutant mitochondrial DNA. Wild-type mtDNA
is depicted in blue and mutant mtDNA is depicted in red with ‘x’
indicating the presence of a mutation. The change in levels of
heteroplasmy affects the clinical and biochemical phenotype.
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designed and validated [4,90–93], thus exhibiting the
potential to target any mutated mtDNA sequence.
All the experimental works using mitochondria-tar-
geted endonucleases have been performed ex vivo on
cultured cells or in vivo on mice. The expression of
these nucleases in patients’ tissues, together with emer-
gent genome editing technologies, has a strong thera-
peutic potential and may constitute a powerful tool to
improve the health of people affected by mitochondrial
disease.
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